Acadia Pharmaceuticals to Sell Rare Pediatric Disease Priority Review Voucher

Dow Jones

Nov 06, 2024

By Sabela Ojea

Acadia Pharmaceuticals said it is selling its rare pediatric disease priority review voucher for $150 million.

The biotechnology company on Tuesday said it plans to invest the proceeds from the sale toward research and development programs in central nervous system and rare diseases.

The company didn't reveal the name of the buyer.

Acadia Pharmaceuticals said the definitive asset purchase agreement came after it was granted the priority review voucher in March 2023 following the Food and Drug Administration approval of Daybue for the treatment of Rett syndrome.

Daybue was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018, so Acadia is required to pay Neuren one-third of the net proceeds, it said.

Rett syndrome is a genetic disorder that affects the nervous system.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

November 05, 2024 17:19 ET (22:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2481506136"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481506136\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2481506136?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 06:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481506136","market":"fut","top_or_hot":-1,"title":"Acadia Pharmaceuticals to Sell Rare Pediatric Disease Priority Review Voucher","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Acadia Pharmaceuticals said it is selling its rare pediatric disease priority review voucher for $150 million. \n</p>\n<p>\n  The biotechnology company on Tuesday said it plans to invest the proceeds from the sale toward research and development programs in central nervous system and rare diseases. \n</p>\n<p>\n  The company didn't reveal the name of the buyer. \n</p>\n<p>\n  Acadia Pharmaceuticals said the definitive asset purchase agreement came after it was granted the priority review voucher in March 2023 following the Food and Drug Administration approval of Daybue for the treatment of Rett syndrome. \n</p>\n<p>\n  Daybue was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018, so Acadia is required to pay Neuren one-third of the net proceeds, it said. \n</p>\n<p>\n  Rett syndrome is a genetic disorder that affects the nervous system. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2024 17:19 ET (22:19 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Pharmaceuticals to Sell Rare Pediatric Disease Priority Review Voucher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Pharmaceuticals to Sell Rare Pediatric Disease Priority Review Voucher\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-06 06:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Acadia Pharmaceuticals said it is selling its rare pediatric disease priority review voucher for $150 million. \n</p>\n<p>\n  The biotechnology company on Tuesday said it plans to invest the proceeds from the sale toward research and development programs in central nervous system and rare diseases. \n</p>\n<p>\n  The company didn't reveal the name of the buyer. \n</p>\n<p>\n  Acadia Pharmaceuticals said the definitive asset purchase agreement came after it was granted the priority review voucher in March 2023 following the Food and Drug Administration approval of Daybue for the treatment of Rett syndrome. \n</p>\n<p>\n  Daybue was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018, so Acadia is required to pay Neuren one-third of the net proceeds, it said. \n</p>\n<p>\n  Rett syndrome is a genetic disorder that affects the nervous system. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2024 17:19 ET (22:19 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4080","symbol_name":"零售业房地产投资信托","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481506136","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481506136","pubTimestamp":1730845140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Acadia Pharmaceuticals said it is selling its rare pediatric disease priority review voucher for $150 million.The biotechnology company on Tuesday said it plans to invest the proceeds from the sale toward research and development programs in central nervous system and rare diseases.The company didn't reveal the name of the buyer.Acadia Pharmaceuticals said the definitive asset purchase agreement came after it was granted the priority review voucher in March 2023 following the Food and Drug Administration approval of Daybue for the treatment of Rett syndrome.Daybue was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018, so Acadia is required to pay Neuren one-third of the net proceeds, it said.Rett syndrome is a genetic disorder that affects the nervous system.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4080":"零售业房地产投资信托","ACAD":"阿卡迪亚","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","AKR":"阿卡迪亚房地产信托","BK4231":"零售房地产信托"},"translate_title":"阿卡迪亚制药公司将出售罕见儿科疾病优先审查券","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKR":1,"ACAD":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Acadia Pharmaceuticals said it is selling its rare pediatric disease priority review voucher for $150 million. \n\n\n  The biotechnology company on Tuesday said it plans to invest the proceeds from the sale toward research and development programs in central nervous system and rare diseases. \n\n\n  The company didn't reveal the name of the buyer. \n\n\n  Acadia Pharmaceuticals said the definitive asset purchase agreement came after it was granted the priority review voucher in March 2023 following the Food and Drug Administration approval of Daybue for the treatment of Rett syndrome. \n\n\n  Daybue was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018, so Acadia is required to pay Neuren one-third of the net proceeds, it said. \n\n\n  Rett syndrome is a genetic disorder that affects the nervous system. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2024 17:19 ET (22:19 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}